News & Articles

Gene Therapy for Lowe Syndrome Glaucoma

New Research Brings Gene Therapy for Lowe Syndrome Glaucoma a Step Closer

Glaucoma is one of the most serious eye problems linked to Lowe Syndrome, affecting around half of all patients and often leading to progressive sight loss. Until now, researchers have struggled to study it properly because animal models don’t reproduce the eye symptoms seen in people. A new study from the Department of Ophthalmology at Stanford University School of Medicine, published in Advanced Science in September 2026, may help change that.

The team took cells from Lowe Syndrome patients and turned them into stem cells. They then grew these into trabecular meshwork cells, the tissue that controls the drainage of fluid from the eye. When this tissue doesn’t work properly, pressure builds up inside the eye and causes glaucoma. Using these patient-derived cells, the researchers tested two different gene therapy approaches.

The first approach was gene augmentation, which delivers a healthy copy of the OCRL gene into the cells using a harmless virus. Because it doesn’t depend on which mutation a person has, it could one day help many patients. Of the three delivery viruses tested, one called AAV2 performed best, and the researchers identified it as a leading candidate for future treatment. The second approach used CRISPR base editing to correct one patient’s specific genetic mutation directly. This restored the OCRL enzyme to normal activity levels and repaired many of the cell defects linked to the condition.

It’s important to be clear that this work was carried out on cells in a laboratory, not in patients, and the researchers note that real challenges remain before any treatment could reach clinical trials. Still, the results show for the first time that both approaches can work in human eye cells affected by Lowe Syndrome. That is a genuinely hopeful step for families living with the condition.

You can read the full study here: CRISPR and Gene Augmentation Rescue Trabecular Meshwork Dysfunction in iPSC Models of Lowe Syndrome